First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring

Fruscalzo, A; Cividino, Adriana; Rossetti, Emma; Maurigh, Alessia; Londero, Ambrogio P.; Driul, Lorenza

doi:10.1038/s41598-020-61830-5

Cited by 17 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Altered serum levels of PAPP-A have been observed to be associated not only with FGR but also gestational diabetes and PE [222,223]. Long-term studies have found that this measurement is also associated with short stature in offspring and maternal diabetes mellitus in later life [224]. For this reason, this biomarker is key in the first trimester for a sooner prediction of placental health and prenatal outcomes to classify patients with increased risk of FGR [225].…”

Section: Screening Predictive and Diagnostic Biomarkersmentioning

confidence: 99%

The Pivotal Role of the Placenta in Normal and Pathological Pregnancies: A Focus on Preeclampsia, Fetal Growth Restriction, and Maternal Chronic Venous Disease

Ortega

Fraile-Martínez

García-Montero

et al. 2022

Cells

View full text Add to dashboard Cite

The placenta is a central structure in pregnancy and has pleiotropic functions. This organ grows incredibly rapidly during this period, acting as a mastermind behind different fetal and maternal processes. The relevance of the placenta extends far beyond the pregnancy, being crucial for fetal programming before birth. Having integrative knowledge of this maternofetal structure helps significantly in understanding the development of pregnancy either in a proper or pathophysiological context. Thus, the aim of this review is to summarize the main features of the placenta, with a special focus on its early development, cytoarchitecture, immunology, and functions in non-pathological conditions. In contraposition, the role of the placenta is examined in preeclampsia, a worrisome hypertensive disorder of pregnancy, in order to describe the pathophysiological implications of the placenta in this disease. Likewise, dysfunction of the placenta in fetal growth restriction, a major consequence of preeclampsia, is also discussed, emphasizing the potential clinical strategies derived. Finally, the emerging role of the placenta in maternal chronic venous disease either as a causative agent or as a consequence of the disease is equally treated.

show abstract

Section: Screening Predictive and Diagnostic Biomarkersmentioning

confidence: 99%

The Pivotal Role of the Placenta in Normal and Pathological Pregnancies: A Focus on Preeclampsia, Fetal Growth Restriction, and Maternal Chronic Venous Disease

Ortega

Fraile-Martínez

García-Montero

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…The incidence of chromosomal abnormalities, structural malformation and fetal loss will be significantly increased after the occurrence of horizontal abnormalities. [12][13] It was proposed in a study by Fruscalzo et al 14 that PAPP-A level changes may also occur in some pregnancy complications, such as placental abruption, spontaneous abortion, small-for-gestational age, premature rupture of membranes, stillbirth, preeclampsia, and fetal growth retardation suggesting that PAPP-A level changes have important scientific value in pregnation-related studies. 15 This study showed that the total incidence of preeclampsia and the incidence of early-onset preeclampsia, chromosome abnormality, fetal demise and smallfor-gestational age infants were significantly higher in the decreased PAPP-A group than in the normal PAPP-A group, and the incidence of chromosome abnormality and fetal demise was significantly higher in the increased PAPP-A group than in the normal control group, indicating that PAPP-A abnormality will increase the incidence of preeclampsia, chromosomal abnormalities, fetal demise, and small-for-gestational age infants.…”

Section: Discussionmentioning

confidence: 99%

Prediction performance of serum placental growth factor (PLGF) human chorionic gonadotropin β (β-hCG) and PAPP-A levels in early pregnancy for pregnancy outcomes

X¹,

Wang²,

Li³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To investigate the prediction performance of serum placental growth factor (PLGF), free human chorionic gonadotropin β (β-hCG) and pregnancy-associated plasma protein A (PAPP-A) levels in early pregnancy for pregnancy outcomes. Methods: A total of 4256 pregnant women who underwent obstetric examinations in our hospital from June 2018 to June 2020 and completed their full pregnancy were included in the study. The clinical pregnancy outcomes of pregnant women with different PLGF, PAPP-A and β-hCG levels in early pregnancy were recorded, and the prediction performance of the above indicators for adverse pregnancy outcomes was discussed. Results: Pregnant women with increased or decreased PLGF or increased PAPP-A or β-hCG had significantly higher incidence of adverse pregnancy outcomes than normal pregnant women. Pregnant women with abnormal pregnancy had significantly higher β-hCG and PLGF, and lower PAPP-A than those with normal pregnancy. The sensitivity of serum PLGF, β-hCG and PAPP-A in early pregnancy for predicting adverse pregnancy outcomes was 95.13%, 94.19% and 97.75%, and the specificity was 84.31%, 85.80% and 83.22%, respectively. Conclusions: Serum PLGF, PAPP-A and β-hCG in early pregnancy are more effective in predicting adverse pregnancy outcomes. Clinical monitoring of patients with increased PLGF, decreased PAPP-A, and increased β-hCG should be strengthened, especially the monitoring of antepartum examination and B-ultrasound detection of pregnant women with abnormal indicators in middle and late pregnancy, so as to identify adverse pregnancy outcomes as early as possible and give targeted intervention. doi: https://doi.org/10.12669/pjms.38.7.5248 How to cite this:Guo X, Wang F, Li J, Guo Z, Wang J. Prediction performance of serum placental growth factor (PLGF) human chorionic gonadotropin β (β-hCG) and PAPP-A levels in early pregnancy for pregnancy outcomes. Pak J Med Sci. 2022;38(7):---------. doi: https://doi.org/10.12669/pjms.38.7.5248 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…Fetal growth restriction, which complicates approximately 10% of all pregnancies, alongside preeclampsia, is a contributing factor to preterm deliveries [ 11 ]. Gestational diabetes mellitus and pregestational diabetes mellitus significantly impact pregnancy, maternal, and offspring outcomes (e.g., favoring pregnancy complications, abnormal fetal growth trajectories, or long-term sequels) [ 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Nanotechnologies in Obstetrics and Cancer during Pregnancy: A Narrative Review

Bertozzi

Corradetti

Seriau

et al. 2022

JPM

Self Cite

View full text Add to dashboard Cite

Nanotechnology, the art of engineering structures on a molecular level, offers the opportunity to implement new strategies for the diagnosis and management of pregnancy-related disorders. This review aims to summarize the current state of nanotechnology in obstetrics and cancer in pregnancy, focusing on existing and potential applications, and provides insights on safety and future directions. A systematic and comprehensive literature assessment was performed, querying the following databases: PubMed/Medline, Scopus, and Endbase. The databases were searched from their inception to 22 March 2022. Five independent reviewers screened the items and extracted those which were more pertinent within the scope of this review. Although nanotechnology has been on the bench for many years, most of the studies in obstetrics are preclinical. Ongoing research spans from the development of diagnostic tools, including optimized strategies to selectively confine contrast agents in the maternal bloodstream and approaches to improve diagnostics tests to be used in obstetrics, to the synthesis of innovative delivery nanosystems for therapeutic interventions. Using nanotechnology to achieve spatial and temporal control over the delivery of therapeutic agents (e.g., commonly used drugs, more recently defined formulations, or gene therapy-based approaches) offers significant advantages, including the possibility to target specific cells/tissues of interest (e.g., the maternal bloodstream, uterus wall, or fetal compartment). This characteristic of nanotechnology-driven therapy reduces side effects and the amount of therapeutic agent used. However, nanotoxicology appears to be a significant obstacle to adopting these technologies in clinical therapeutic praxis. Further research is needed in order to improve these techniques, as they have tremendous potential to improve the accuracy of the tests applied in clinical praxis. This review showed the increasing interest in nanotechnology applications in obstetrics disorders and pregnancy-related pathologies to improve the diagnostic algorithms, monitor pregnancy-related diseases, and implement new treatment strategies.

show abstract

First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring

Cited by 17 publications

References 37 publications

The Pivotal Role of the Placenta in Normal and Pathological Pregnancies: A Focus on Preeclampsia, Fetal Growth Restriction, and Maternal Chronic Venous Disease

The Pivotal Role of the Placenta in Normal and Pathological Pregnancies: A Focus on Preeclampsia, Fetal Growth Restriction, and Maternal Chronic Venous Disease

Prediction performance of serum placental growth factor (PLGF) human chorionic gonadotropin β (β-hCG) and PAPP-A levels in early pregnancy for pregnancy outcomes

Nanotechnologies in Obstetrics and Cancer during Pregnancy: A Narrative Review

Contact Info

Product

Resources

About